Dr. Amit Oza is a Senior Staff Physician and Associate Professor of Medicine at Princess Margaret Hospital, University of Toronto. He is a Scientist with the Ontario Cancer Institute and cross appointed to the Department of Obstetrics and Gynecology at the University of Toronto. He graduated from St. Bartholomew's Hospital, University of London (UK), in 1983 and completed his internal medicine and medical oncology training in UK. He completed Clinical Research Fellowships at St. Bartholomew's Hospital/Imperial Cancer Research Fund, London (UK), Princess Margaret Hospital, Toronto and at the Netherlands Cancer Institute, Amsterdam. His postgraduate research thesis was on Molecular Epidemiology of Hodgkin's Disease. He is a Fellow of the Royal College of Physicians of London and Canada.
Dr. Oza has been the principal investigator and co-investigator in phase I, II, and III trials for gynecological cancer and advanced colorectal malignancies. His research interests are focused towards the development, assessment and validation of novel therapeutic strategies for cancer including molecular targeted therapies. Many of these studies also incorporate novel endpoints and translational research which is developed in close relationship with scientists and pathologists from the OCI/PMH.
Dr. Oza has been the recipient of various awards such as the University of Toronto Award for Teaching Excellence for the Medical Oncology Training Program, the Hasselback Award for Teaching Excellence from Princess Margaret Hospital and many others. He has also been principal and co-author of numerous publications in major peer reviewed journals such as Cancer Research, Journal of Clinical Oncology, Annals of Oncology, Investigational New Drugs and Clinical Cancer Research.
He is currently Co-Director of the Robert and Maggie Bras and Family Drug Development Program at Princess Margaret Hospital. This is the largest new drug development program in Canada and the only center outside the US to have a contract with the NIH for Early Phase Therapeutic studies. He is also Co-Chair of the Gynecology Site Committee of the NCIC Clinical Trials Group and represents NCIC CTG at the Gynecologic Cancer Inter Group.
Industry Expertise (7)
Health and Wellness
Training and Development
Health Care - Services
Health Care - Providers
Health Care - Facilities
Areas of Expertise (6)
Award for Teaching Excellence (professional)
Awarded by the University of Toronto for his teaching in the Medical Oncology Training Program
Hasselback Award (professional)
Awarded by the Princess Margaret Hospital
University of London: B.Sc. (Hons), M.B., B.S., M.D. (Lon), FRCPC, FRCP, Medicine 1983
- Royal College of Physicians of London and Canada : Fellow
- Robert and Maggie Bras and Family Drug Development Program : Co-Director
- NCIC Clinical Trials Group : Gynecology Site Committee
- Gynecologic Cancer Inter Group : NCIC CTG Representative
- Ozmosis Research : CEO
Media Appearances (4)
Princess Margaret joins hands with Tata Memorial
At the end of May Princess Margaret Cancer Centre, University Health Network, Toronto and Tata Memorial Centre in Mumbai signed a Memorandum of Understanding (MOU) to pool their cancer knowledge and resources. Can-India spoke with Dr. Amit Oza (Medical Oncologist and Senior Staff Physician, Princess Margaret Cancer Centre, University Health Network (UHN) and Professor of Medicine, University of Toronto), and Senthil Muthuswamy, PhD (Senior Scientist, Princess Margaret Cancer Center, The Campbell Family Institute for Breast Cancer Research, UHN ) who were both instrumental in formalizing this collaboration...
Dr. Amit Oza on cancer treatment breakthrough
Wed, Jun 19: Dr. Amit Oza joins The Morning Show to discuss how researchers have developed a new “sharp-shooter” drug they hope may be a breakthrough in treating several types of cancer...
Avastin use in ovarian cancer may delay disease
"This is the first new drug in ovarian cancer in 15 years to improve outcome and I believe it should be considered as a potential new standard of care," said Dr. Amit Oza, a medical oncologist who leads the Cancer Clinical Research Unit at Princess Margaret Hospital in Toronto, in a release. Oza led the study with Timothy Perren of the St. James Institute of Oncology in Leeds, England...
The Princess Margaret Receives Three Awards from Cancer Care Ontario
The Campbell Family Cancer Research Institute online
The following investigators from The Princess Margaret have received peer-reviewed Applied Cancer Research Unit Awards from Cancer Care Ontario. In commenting on these awards, Dr. Mary Gospodarowicz, Director of The Princess Margaret's Cancer Program said, "The work of all these recognized investigators has been financially supported by The Princess Margaret Hospital Foundation, in the past, and this is an excellent example of how that support has been leveraged to acquire additional funding."
Event Appearances (3)
Serum activinA and TGF-β as biomarkers of breast cancer bone metastasis behavior
ASCO Annual Meeting Chicago, IL.
Best of Oncology Conference Toronto, ON.
Focus on Ovarian Cancer
10th Princess Margaret Hospital Conference Toronto, ON.
A total of 1528 women from 11 countries were randomly assigned to one of the two treatment regimens. Their median age was 57 years; 90% had epithelial ovarian cancer, 69% had a serous histologic type, 9% had high-risk early-stage disease, 30% were at high risk for ...
Vascular endothelial growth factor (VEGF) plays an important role in the biology of ovarian cancer (OC). Inhibitors of VEGF suppress tumor growth in OC models. Metronomic chemotherapy, defined as frequent administration of low doses of cytotoxic chemotherapy, ...
In North America, no effective therapy has been available for patients with progressive metastatic colorectal cancer after front-line treatment with irinotecan, bolus fluorouracil (FU), and leucovorin (IFL). Patients and Methods: Patients with metastatic ...
3-Hydroxy-3-methylgutaryl CoA reductase inhibitors, commonly referred to as the statins, have proven therapeutic and preventative effects in cardiovascular diseases. Recently, there are emerging interests in their use as anticancer agents based on ...
There is now a large amount of evidence showing that mammographic densities are an indicator of increased risk of breast cancer. There is as yet no generally agreed upon and recognized method of classifying these densities, although the available evidence shows ...